Trial Profile
A Pilot Study of Pre-Operative, Single-Dose Ipilimumab, Nivolumab and Cryoablation in Early Stage/Resectable Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Early breast cancer
- Focus Adverse reactions
- 03 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 03 Jul 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 01 Jul 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.